Li Xing, Magro Cynthia M
Physician Resident, Department of Pathology, Montefiore Medical Center/ The University Hospital of Albert Einstein College of Medicine, Bronx, NY; and.
Director and Distinguished Professor, Department of Dermatopathology, Weill-Cornell Medical College and New York Presbyterian Hospital, New York, NY.
Am J Dermatopathol. 2025 Oct 1;47(10):739-749. doi: 10.1097/DAD.0000000000002956. Epub 2025 Jul 24.
Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoproliferative disorder (CD4+ PCSM-LPD) is characterized by its indolent course and favorable prognosis, distinguishing it from multifocal variants or other peripheral T-cell lymphomas. Pediatric cases are exceptionally rare, with only 9 pediatric cases documented, limiting understanding of their clinical, pathological, and molecular characteristics. Although recent studies propose a T follicular helper cell (TFH) origin, further investigation is necessary to substantiate this hypothesis and elucidate the pathogenesis of CD4+ PCSM-LPD in pediatric patients. We conducted a systematic literature review (6 studies documenting 9 cases) and retrospective chart review of pediatric CD4+ PCSM-LPD cases (≤21 years) diagnosed at Weill Cornell Medicine between 2010 and 2024 (4 cases). All 13 cases presented with solitary lesions, lacking the head and neck predominance observed in adult patients. Treatments included intralesional steroids, excision, and local radiation, with no recurrences. Histopathology mirrored adult cases, showing characteristic features of CD4+ PCSM-LPD. Nonspecific TFH markers (PD-1, BCL-6, ICOS) exhibited variable positivity, whereas specific markers (CD10, CXCL13) were predominantly negative. CD4+ PCSM-LPD is a rare entity that can potentially occur in pediatric patients, exhibiting clinical, histopathological, and phenotypic features similar to adult cases. However, the hypothesis of follicular helper T-cell ontogeny is questioned, as specific markers are usually absent, whereas commonly reported positive stains are not specific for follicular helper T cells. This suggests a malleable CD4+ T-cell phenotype influenced by the microenvironment.
原发性皮肤CD4+小/中型多形性T细胞淋巴增殖性疾病(CD4+ PCSM-LPD)的特点是病程惰性且预后良好,这使其有别于多灶性变体或其他外周T细胞淋巴瘤。儿科病例极为罕见,仅有9例儿科病例记录在案,这限制了我们对其临床、病理和分子特征的了解。尽管最近的研究提出其起源于T滤泡辅助细胞(TFH),但仍需进一步研究来证实这一假设,并阐明儿科患者中CD4+ PCSM-LPD的发病机制。我们进行了一项系统的文献综述(6项研究记录了9例病例),并对2010年至2024年间在威尔康奈尔医学院诊断的儿科CD4+ PCSM-LPD病例(≤21岁,4例)进行了回顾性病历审查。所有13例病例均表现为孤立性病变,没有成人患者中常见的头颈部优势。治疗方法包括病灶内注射类固醇、切除和局部放疗,均无复发。组织病理学与成人病例相似,显示出CD4+ PCSM-LPD的特征性表现。非特异性TFH标志物(PD-1、BCL-6、ICOS)表现出不同程度的阳性,而特异性标志物(CD10、CXCL13)大多为阴性。CD4+ PCSM-LPD是一种罕见的疾病,可能发生在儿科患者中,表现出与成人病例相似的临床、组织病理学和表型特征。然而,滤泡辅助T细胞起源的假设受到质疑,因为特异性标志物通常缺失,而常见的阳性染色并非滤泡辅助T细胞所特有。这表明CD4+ T细胞表型具有可塑性,受微环境影响。